Angiotensin II |
| Katalog-Nr.GP10023 |
Ein Agonist an den AT1- und AT2-Rezeptoren.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 4474-91-3
Sample solution is provided at 25 µL, 10mM.
Angiotensin II is a vasoconstrictor and the main bioactive peptide of the renin/Angiotensin system. Angiotensin II human plays a central role in the regulation of human blood pressure, mainly through Angiotensin II and G protein-coupled receptors(GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R) interact to mediate[1].
Human induces capillary formation in endothelial cells through a LOX-1-dependent redox-sensitive pathway. Angiotensin II (1 nM) induces the expression of LOX-1 and VEGF and enhances capillary formation from human coronary endothelial cells in Matrigel assay[3,4].Angiotensin II helps to regulate overall renal tubular reabsorption of salt and water, Angiotensin II directly stimulates epithelial sodium channel activity through an AT1 receptor-dependent mechanism[8].Angiotensin II Human induces the growth of vascular smooth muscle cells, increases the synthesis of collagen type I and III in fibroblasts, leads to the thickening of the vascular wall and myocardium, and induces fibrosis. Angiotensin II also induces apoptosis[2].The effects of Angiotensin II to increase blood pressure are mediated by AT1 receptors[1], and these receptors are expressed in a variety of organ systems thought to play key roles in blood pressure homeostasis, including the heart, kidney, blood vessels, adrenal glands, and cardiovascular control centers in the brain[5]. In the brain, intraventricular injection of Angiotensin II causes a dramatic pressor response that is mediated by AT1A receptors[6].
In mice, AT1 receptors in the kidney are primarily responsible for the actions of Angiotensin II to cause hypertension[7]. Angiotensin II induction of NETosis in vitro via ROS/ peptidyl arginine deiminase type 4 and autophagy dependent pathways In EH patients initiated with Angiotensin II receptor blockers, circulating NETs and thrombin production levels were significantly reduced, whereas their plasma was unable to trigger procoagulant NETs [9].
References:
[1]: de Gasparo M, Catt KJ, et,al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000 Sep;52(3):415-72. PMID: 10977869.
[2]: Fyhrquist F, Mets?rinne K, et,al. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens. 1995 Nov;9 Suppl 5:S19-24. PMID: 8583476.
[3]: Hu C, Dandapat A, et,al. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway. Hypertension. 2007 Nov;50(5):952-7. doi: 10.1161/HYPERTENSIONAHA.107.096446. Epub 2007 Sep 24. PMID: 17893372.
[4]: Nabah YN, Mateo T, et,al. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation. 2004 Dec 7;110(23):3581-6. doi: 10.1161/01.CIR.0000148824.93600.F3. Epub 2004 Nov 29. PMID: 15569833.
[5]: Shanmugam S, Sandberg K. Ontogeny of angiotensin II receptors. Cell Biol Int. 1996 Mar;20(3):169-76. doi: 10.1006/cbir.1996.0021. PMID: 8673065.
[6]: Davisson RL, Oliverio MI, et,al. Divergent functions of angiotensin II receptor isoforms in the brain. J Clin Invest. 2000 Jul;106(1):103-6. doi: 10.1172/JCI10022. PMID: 10880053; PMCID: PMC314366.
[7]: Crowley SD, Gurley SB, et,al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17985-90. doi: 10.1073/pnas.0605545103. Epub 2006 Nov 7. PMID: 17090678; PMCID: PMC1693859.
[8]: Peti-Peterdi J, Warnock DG, et,al. Angiotensin II directly stimulates ENaC activity in the cortical collecting duct via AT(1) receptors. J Am Soc Nephrol. 2002 May;13(5):1131-5. doi: 10.1097/01.asn.0000013292.78621.fd. PMID: 11960999.
[9]: Chrysanthopoulou A, Gkaliagkousi E, et,al. Angiotensin II triggers release of neutrophil extracellular traps, linking thromboinflammation with essential hypertension. JCI Insight. 2021 Sep 22;6(18):e148668. doi: 10.1172/jci.insight.148668. PMID: 34324440; PMCID: PMC8492353.
| Cell experiment [1]: | |
|
Cell lines |
HCAEC cells |
|
Preparation Method |
HCAECs were exposed to Angiotensin II (0, 0.1, 1, 5, 10, 20, 50, and 100 nmol/L) for 24 hours. |
|
Reaction Conditions |
Angiotensin II (0, 0.1, 1, 5, 10, 20, 50, and 100 nmol/L) for 24 hours |
|
Applications |
Angiotensin II (1 nM) induces the expression of LOX-1 and VEGF and enhances capillary formation from human coronary endothelial cells in Matrigel assay. Angiotensin II -mediated expression of LOX-1 and VEGF, capillary formation, intracellular reactive oxygen species generation, and phosphorylation of p38 as well as p44/42 mitogen-activated protein kinases, are suppressed by anti-LOX-1 antibody, nicotinamide-adenine dinucleotide phosphate oxidase inhibitor apocynin and the Angiotensin II type 1 receptor blocker Losartan, but not by the Ang II type 2 receptor blocker PD123319. |
| Animal experiment [2]: | |
|
Animal models |
(129 × C57BL/6) F1 mice lacking AT1A receptors |
|
Preparation Method |
To distinguish the AT1 receptor population that is critical for the pathogenesis of hypertension, osmotic minipumps were implanted s.c. into each animal to infuse Angiotensin II (1,000 ng/kg/min) continuously for 4 weeks. |
|
Dosage form |
Angiotensin II (1,000 ng/kg/min) for 4 weeks. |
|
Applications |
AT1 receptors in the kidney are primarily responsible for the actions of Angiotensin II to cause hypertension. |
|
References: [1]: Hu C, Dandapat A, et,al. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway. Hypertension. 2007 Nov;50(5):952-7. doi: 10.1161/HYPERTENSIONAHA.107.096446. Epub 2007 Sep 24. PMID: 17893372. |
|
| Cas No. | 4474-91-3 | SDF | |
| Chemical Name | Angiotensin II | ||
| Canonical SMILES | CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(CC3=CC=CC=C3)C(=O)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N.CC(=O)O | ||
| Formula | C50H71N13O12 | M.Wt | 1046.2 |
| Löslichkeit | ≥100.2mg/mL in Water | Storage | Store at -20°C, protect from light, stored under nitrogen |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.9558 mL | 4.7792 mL | 9.5584 mL |
| 5 mM | 0.1912 mL | 0.9558 mL | 1.9117 mL |
| 10 mM | 0.0956 mL | 0.4779 mL | 0.9558 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *